CJC-1295 and Ipamorelin After the Richard Norton Peptide Death: Federal and Florida Exposure for Sellers, Prescribers and Med Spas

A licensed doctor prescribed it and a licensed compounding pharmacy made it. On March 30, 2025, Australian actor and stuntman Richard Norton died after injecting it. On October 28, a Victorian coroner found his death was triggered by an injection of two unapproved peptides, CJC-1295 and ipamorelin. Sold as a growth hormone stack, the pair is a fixture on U.S. research peptide websites and med spa menus. A named death tied to a specific product changes how investigators, prosecutors and juries look at everyone who sold it.

A named death tied to a specific product changes how investigators, prosecutors and juries look at everyone who sold it.

Key Takeaways

• An Australian coroner found that prescribed, pharmacy-compounded CJC-1295 and ipamorelin triggered actor Richard Norton's fatal cardiac arrest in March 2025.
• FDA had already flagged both peptides for significant safety risks, and neither is among the six peptides covered by HHS's October 2026 compounding policy.
• Selling either peptide for human use exposes U.S. sellers to misbranding and unapproved new drug charges under 21 U.S.C. §§ 331 and 333.
• In Florida, a contraband prescription drug sale resulting in death is a first-degree felony punishable by up to life under Fla. Stat. § 499.0051(9).
• A prescription does not legalize an unapproved peptide; it adds the prescriber and the compounding pharmacy to the list of people investigators interview.

What the Coroner Found in the Richard Norton Case

Norton was 75. According to ABC News, he sought peptide therapy for fatigue, slow recovery, shoulder pain and lost muscle mass. His doctor prescribed CJC-1295 and ipamorelin for injection, and a licensed compounding pharmacy in Queensland made them. Days before his death, he told a clinic nurse he had been injecting double the prescribed dose. The coroner found the injection set off a severe allergic reaction that led to cardiac arrest.

Australia's medical board cautioned the prescribing doctor, and a reviewing expert called his notes "sparse, inadequate and perfunctory." The coroner asked Australia's drug regulator to consider limiting these peptides to clinical trials. It is believed to be the first death in Australia attributed to unapproved peptide use.

"sparse, inadequate and perfunctory."— Reviewing expert, on the prescribing doctor's notes in the Richard Norton case

Nothing about this case was fringe: a prescription, a licensed pharmacy, a patient who said he felt better. Defense lawyers will point to the double dose. Prosecutors will answer with the seller's own dosing chart, which shows the seller expected the product to go into a human body.

What U.S. Regulators Already Said About CJC-1295 and Ipamorelin

FDA's list of bulk drug substances that may present significant safety risks has carried ipamorelin acetate in category 2 under the 503B interim policy since September 29, 2023, citing immunogenicity risk and a published study reporting serious adverse events, including death. The same page lists CJC-1295 as a substance with potential significant safety risks, citing increased heart rate and a systemic vasodilatory reaction. Immunogenicity means immune reactions, and anaphylaxis is the most dangerous kind.

The enforcement discretion policy published in the Federal Register on October 30 covers six peptides compounded by licensed pharmacies and physicians under ten conditions: BPC-157, TB-500, epitalon, KPV, MOTS-c and Semax. No seller of CJC-1295 or ipamorelin can point to it. See our analysis of the HHS peptide policy.

FDA warning letters to research use only peptide sellers keep coming, and in July a federal judge in Indiana sentenced the owner of an online peptide business to 70 months in federal prison in a case built on unapproved drug sales. In July 2025, two women were hospitalized in critical condition after peptide injections at a Las Vegas conference, prompting Nevada investigations.

Investigators work these cases backward from the patient: hospital record to product, vial to seller, seller's order system and certificates of analysis to supplier, lot and every other buyer. That is how one adverse event becomes an FDA OCI investigation of an entire catalog.

Investigators work these cases backward from the patient: hospital record to product, vial to seller, and seller to supplier, lot and every other buyer.

How a Death Changes the Charges: Florida Law First, Then Federal

Florida punishes a death more severely than federal drug law does. Selling a misbranded drug is a second-degree misdemeanor under Fla. Stat. § 499.0051(11), and a second-degree felony when done knowingly under § 499.0051(13). The heavier provisions apply to contraband prescription drugs, which Fla. Stat. § 499.003(11) defines to include adulterated drugs and prescription drugs that move without the required transaction history. A knowing sale that results in great bodily harm is a first-degree felony under § 499.0051(8). One that results in death is a first-degree felony punishable by up to life under § 499.0051(9). Whether a vial meets that definition is litigable, but a South Florida seller expecting a regulatory fine is reading the wrong statute.

Federal law has no death-results provision for unapproved peptides like the one 21 U.S.C. § 841 carries for controlled substances. The core charge is misbranding under 21 U.S.C. § 331 or sale of an unapproved new drug under § 355: a misdemeanor without proof of intent under § 333(a)(1), and a three-year felony with intent to defraud or mislead under § 333(a)(2). Section 331 reaches anyone who causes a prohibited act, which is how prescribers and pharmacies end up in the seller's case. A death still matters in three ways:

• Charging. A matter FDA might have closed with a warning letter becomes a criminal referral.
• Stacking. Marketing that misrepresented safety or testing supports wire fraud under 18 U.S.C. § 1343, and imported product supports smuggling under 18 U.S.C. § 545. Each carries 20 years.
• Sentencing. The fraud guideline, USSG § 2B1.1, adds two levels for conscious or reckless risk of death or serious bodily injury, and courts weigh harm under 18 U.S.C. § 3553(a).

Why a Research Label or a Prescription Will Not Hold

Two expected defenses are weak. A research use only label does not control, because 21 C.F.R. § 201.128 judges intended use from the seller's objective intent. A prescription does not legalize the product either. Compounding is exempt from new drug approval only under the conditions of 21 U.S.C. § 353a, and neither peptide is on the 503A bulks list or in category 1 of FDA's interim policy. In the United States, the chain that supplied Norton would be an introduction of unapproved new drug case.

Mistakes Sellers, Prescribers and Med Spas Make After an Adverse Event

A South Florida med spa sells a client a CJC-1295 and ipamorelin vial from a research peptide supplier. Weeks later his wife calls from intensive care. The owner deletes the product page, asks the supplier for a new certificate of analysis, and tells the hospital the vial was "for research." All three steps are now evidence: of obstruction, of manufactured records and of intent.

Deleting the product page, asking for a new certificate of analysis, telling the hospital the vial was for research: all three steps are now evidence.

• Deleting or editing. Removing pages, revising certificates or wiping chats after a serious reaction invites a charge under 18 U.S.C. § 1519, even before an investigation opens.
• Explaining. Statements to a hospital, an inspector or a family's lawyer become evidence of intent, and intent separates the misdemeanor from the felony.
• Selling the same lot. Every sale after notice of a reaction strengthens the intent case.
• Waiting for paper. A federal grand jury subpoena or a letter from the U.S. Attorney's Office is a late moment to call counsel.

How These Matters Get Defended

The first work is preservation and fact-finding under privilege: which lot, which supplier, which certificate, and what the business said about the product. Sellers then decide whether to stop selling, how to handle inventory and whether to file an adverse event report, with a peptide attorney involved in each. Pharmacies and prescribers need a 503A compounding pharmacy attorney to test whether each product fit section 503A, and med spas that resold inventory need a med spa attorney who knows both sides.

Once agents call or a federal grand jury subpoena arrives, the work is federal investigation defense: learning whether the client is a witness, subject or target and reaching the prosecutor while charging decisions are open. It is the work a federal target letter attorney does, and in Southern District of Florida federal defense practice it is where any chance to avoid indictment exists. Those calls belong with a federal criminal defense attorney or white collar defense attorney. Employees who handled product need their own counsel.

Why the Next Few Weeks Matter

The Norton findings reached U.S. audiences this week, alongside an HHS policy that leaves both peptides out. Reporters, plaintiffs' lawyers and investigators read the same coverage. If a customer has told your business about a serious reaction, that record already exists. What you do now about preservation, statements and continued sales decides how the file reads when charging decisions are made.

Common Questions

Facing a Peptide or FDA Investigation in Florida?

AMC Defense Law represents peptide sellers, compounding pharmacies, prescribers and med spa operators in FDA and federal criminal investigations, from Boca Raton and in federal districts nationwide. If a customer has reported a serious reaction, or you have received an FDA warning letter, a federal grand jury subpoena or a letter from the U.S. Attorney's Office, contact the firm for a confidential consultation before you respond. Call 561-542-5494 or email amc@amcdefenselaw.com.

Aaron M. Cohen, AMC Defense Law, Boca Raton.

If you or your loved ones have been arrested or are under federal investigation in a peptide or FDA matter, call Aaron M. Cohen, 24 hours a day to get help.

About the author: Aaron M. Cohen is the founder and principal attorney of AMC Defense Law, a criminal defense firm in Boca Raton, Florida, with more than 30 years of experience in state and federal courts. He is admitted to practice in Florida, New York, New Jersey, and the District of Columbia, and before the United States District Courts for the Southern and Middle Districts of Florida, the Southern, Eastern, and Western Districts of New York, the District of New Jersey, and the Northern District of Texas. He appears pro hac vice in other federal districts nationwide. The firm represents clients in federal investigations and prosecutions involving healthcare fraud, Anti-Kickback Statute matters, DME and telemedicine fraud, peptide and compounded-drug enforcement, controlled-substance and drug conspiracy cases, financial crimes, and complex federal litigation, in Florida and nationwide.

This article is provided for general informational purposes only. It is not legal advice, and it does not create an attorney-client relationship. Every case is different, and outcomes depend on the specific facts and law involved. The coroner's findings discussed here were issued in Victoria, Australia, and are described as reported by the news organizations cited. If you are facing an investigation or charges, consult a qualified attorney about your specific situation.